top of page

Pediatric DTG FAQs

  • hivtoolkit
  • Oct 12, 2021
  • 1 min read

Updated: Jan 13, 2022


This document is meant to assist national HIV programs in pDTG adoption. This document provides a summary of pDTG, including advantages over other ARVs, cost, dosing, administration, side effects, and transition considerations.


Comments


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page